ProUroCare Medical Inc. Stock Analysis PUMD
ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.
Read More ProUroCare Medical Inc (PUMD) Chart
Key Statistics of ProUroCare Medical Inc (PUMD)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
72.05KP/E Ratio (TTM)
-52 Week Range
Market Cap
1860.00Avg. Volume
46.03KDividend Yield
-Financial Metrics & Statements of ProUroCare Medical Inc (PUMD)
FAQ's for ProUroCare Medical Inc (PUMD)
- According to Musaffa’s Shariah screening methodology, ProUroCare Medical Inc (PUMD) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.